---
title: Determine cancer risk in Parkinson
nct_id: NCT06814431
status: RECRUITING
sponsor: Azienda USL Reggio Emilia - IRCCS
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06814431"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06814431"
last_fetched: "2026-05-10T14:01:39.316Z"
source: "Parkinson's Pathways (curated)"
---
# Determine cancer risk in Parkinson

**Goal (in five words):** Determine cancer risk in Parkinson

**Official Title:** Study on the Incidence of Malignant Neoplasms in Patients with Parkinson's Disease and Heterozygous Mutation of the GBA Gene

**Trial ID:** [NCT06814431](https://clinicaltrials.gov/study/NCT06814431)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Azienda USL Reggio Emilia - IRCCS
- **Target Enrollment:** 3000 participants
- **Start Date:** 2023-11-23
- **Completion Date:** 2025-12
- **Conditions:** Idiopathic Parkinson's Disease (PD)

## Summary For Families

Researchers want to know whether people with Parkinson's who carry a single (heterozygous) mutation in the GBA gene have higher rates of malignant cancers than other people with Parkinson's. They will follow about 3,000 adults with Parkinson's, determine who has a heterozygous GBA mutation, and track new cancer diagnoses through medical records and registries; since the work is observational, no experimental treatment is given. GBA makes the enzyme glucocerebrosidase, which helps lysosomes clear cellular waste, and reduced enzyme activity can alter cell biology in ways that might influence cancer risk, so the study is looking for those patterns. Adults 18 and older with Parkinson's confirmed by the UK Brain Bank criteria are eligible, people with an uncertain diagnosis are excluded.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* \>18 years
* Diagnosis of Parkinson's Disease through the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria for Parkinson's Disease.

Exclusion Criteria:

* Uncertain diagnosis
```

## Locations (4)

- Ospedale A. Perrino, Brindisi, Italy _(40.6322, 17.9361)_
  - Francesca Spagnolo, MD — (CONTACT) — francesca.spagnolo@asl.brindisi.it
  - Francesca Spagnolo, MD — (CONTACT)
- IRCCS Istituto Neurologico Carlo Besta, Milan, Italy _(42.7824, 12.5984)_
  - Roberto Cilia, MD — (CONTACT) — roberto.cilia@istituto-besta.it
  - Roberto Cilia, MD — (CONTACT)
- Azienda USL IRCCS di Reggio Emilia, Reggio Emilia, Italy _(44.6983, 10.6312)_
  - Giulia Toschi, Clinical Research Coordinator — (CONTACT) — +390522295565
  - Franco Valzania, MD — (CONTACT)
- Ospedale Santa Chiara di Trento, Trento, Italy _(46.0679, 11.1211)_
  - Maria Chiara Malaguti, MD — (CONTACT) — mariachiara.malaguti@apss.tn.it
  - Maria Chiara Malaguti, MD — (CONTACT)

## Central Contacts

- Franco Valzania, MD — (CONTACT) — +39 0522 296494 — franco.valzania@ausl.re.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT06814431*  
*HTML version: https://parkinsonspathways.com/trial/NCT06814431*  
*Source data: https://clinicaltrials.gov/study/NCT06814431*